Idera Pharmaceuticals, Inc.
0.44 - 0.52
0.295 - 1.71
Join Discuss about IDRA with like-minded investors
**GUERRA IN UCRAINA** (News della sera) In reazione all'accordo tra Stati Uniti, Regno Unito e Australia sulle armi ipersoniche, il rappresentante cinese delle Nazioni Unite mette in guardia da eventi che potrebbero trascinare in conflitto altre parti del mondo, come l'Ucraina. Gli Stati Uniti hanno sanzionato IDRA con sede in Russia, così come il cambia valute Garantex. Il Tesoro degli Stati Uniti ha sanzionato il mercato russo IDRA Darknet. JPMorgan consente ai titolari di ricevute di deposito emesse da società russe di annullarle. - Fonte. Senatori a Biden: alzare le tariffe statunitensi sull'acciaio ucraino. **Wunsch della BCE: nel lungo periodo, i tassi della BCE potrebbero crescere dall'1,5% al 2%. L'obiettivo di inflazione è stato in gran parte raggiunto e il tasso sui depositi sarà portato a zero entro la fine dell'anno.** Casa Bianca: Gli Stati Uniti non vedono variazioni dell'appartenenza della Russia al Consiglio di sicurezza delle Nazioni Unite. WH Psaki: L'obiettivo degli Stati Uniti è di esaurire le risorse di Putin per la guerra in Ucraina. L'obiettivo è fare in modo che la Russia scelga tra il default e il prosciugamento delle sue riserve in dollari. Gli Stati Uniti stanno collaborando con altri paesi per aumentare la fornitura di petrolio. Il nuovo round di misure russe arriverà in risposta agli omicidi di Bucha. Gli Stati Uniti esamineranno i metodi per assistere l'Europa con proprie forniture di energia. Gli Stati Uniti continueranno a studiare metodi per ridurre la dipendenza dell'Europa dal gas naturale russo. Pentagono: Il Dipartimento di Stato degli Stati Uniti ha approvato una possibile vendita di supporto e equipaggiamento per il sistema di difesa aerea Patriot a Taiwan per un costo stimato di 95 milioni di dollari.
43 Replies 15 👍 12 🔥
IU Free Sunday watchlist: $LCID I think will continue to provide opportunity daily opportunity the next few days. Any big gap downs and flushes likely met with an aggressive rebound any good gap ups and over extensions likely met with a fade opportunity. Not really coming in with a bias here it's just been a fantastic trader the last few days $SFIX thinking this may stay heavy looking to join failed follow through 945-10AM + as long as $20s doesn't start to firm a base. $F any weak open likely absorbed - figured we'd have that flush out to sub $18 before this break out but got to mid $18s and hasn't looked back since. Be cautious thinking it ripped too far this move has been consolidating for a month although it's possible it could hit wall and fade off I think it's important to understand it's literally been a month of sideways before this move so this may take 2-3 days to build and have a secondary leg up. Failed Follow Through: $IINN higher better in the AM ideally and then looking for failed follow through. $ENSC some great volume day 1 and day 3 but I think they blew most shorts out - I would not ASSUME it's over but good chance that if the volume continues to be super low sorta the beginning of the back side of the move. $CNTX may not be as much of an opportunity as Friday's but watch pops and failed follow through could see it breach that $5 level after any follow through action pre market (gap etc). $MTTR continues to fail - higher better and ideally back towards that $20 magnet. $ISIG killer opportunity Thursday and Friday - definitely for the fridge but -- watch all pops stay away from SIZE stay away from front side w/o some sorta exchange or transition. Continuation: $EFOI I had this on the failed follow through part but looking at the wicks on the daily make me think it's possible it's not done. I want to see it PROVE it has more vs. assume. $SGMA monster - great alert by DividedChamp on Friday on the e/r got long and added all day sold some as high as $18.40s AHs -- insane. Kept rest over but ideally they walk it down pre market into open and trap providing a spot to add back some of the sells. $AVCT great short on Friday and they filed the 424 but relatively small so if people were positioned b/c they knew they were going to raise and didn't think too much about the volume vs. # of shares they could raise they're prob still twisted. We could have a nice secondary shove if dips get absorbed on Monday. $PTPI as much as it keeps failing it keeps hanging which interest me. $3.50 clearly the big level - I've probably traded this long swing the most poorly b/c I've had a great average been up so much but each time it's pre 7AM when its $4-5 and I have it at Etrade so I can't do anything about it. $IDRA nothing exciting - still long from the patent seems like it's hanging .90 is the key. $VYNE feels like if $1.40-1.50 bases we could have secondary move.
51 Replies 11 👍 9 🔥
Milpower1967 Any good selling premium stock today > @Milpower1967 said: $IDRA has incredible premium right now for 4/16 $4 put. Just sayin'. Next, closed $OCGN CCs expiring this week for a 63% gain and then sold next months at $15 for another $1.50 each. Cost basis for $OCGN is $8.13 with plenty of upside at $15 strike. :)
112 Replies 11 👍 9 🔥
If you don't really care about owning $IDRA and are just in it for the premium, perhaps. If you like the stock and love it even more for a .30 price reduction, it's not. To each their own I suppose. I'm recovered ALL my earlier losses a few weeks ago by using CSPs and CCs. These are the safest, most reliable, most conservative trades a person can do. If you think otherwise, I think you are misinformed.
81 Replies 14 👍 6 🔥
Next Dividend Date
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
CEO: Vincent Milano
HQ: 505 Eagleview Blvd Ste 212 Exton, 19341-1199 Pennsylvania